The Ultimate Guide to Dividend Stocks

The Ultimate Guide to Dividend Stocks

The stock of companies that pay out a portion of their earnings to a class of shareholders on a regular basis are known as Dividend Stocks. Dividend investing provides investors with steady cash flow over the long term. Most dividends are paid out on a quarterly basis, but some are paid out monthly, annually, or even once in the form of a special dividend.

Larger, established companies with predictable profits are often the best dividend payers and industry sectors such as Basic Materials, Oil & Gas, Banks & Financial, Health Care and Utilities maintain a regular record of dividend payments

Hitch a ride to the EV boom with Blink Charging Co. (NASDAQ:BLNK)

Hitch a ride to the EV boom with Blink Charging Co. (NASDAQ:BLNK)

Blink Charging Co. (XNAS: BLNK) provides electric vehicle (EV) charging equipment and networked EV charging services in the United States and internationally. The Company was founded in 2009 and is headquartered in Miami Beach, Florida.

Blink offers residential and commercial EV charging equipment that enable EV drivers to recharge at various location types. The company offers its services through direct sales force and resellers, as well as sells residential Level 2 chargers through various internet channels.

Is this oil stock too good a bargain to ignore: Parex Resources (TSE:PXT)?

Is this oil stock too good a bargain to ignore: Parex Resources (TSE:PXT)?

Parex Resources Inc. (XTSE: PXT) is a crude oil exploration, development, and production company. The business utilizes technologies developed in Western Canada’s Sedimentary Basin to South American basins with significant oil-in-place potential. The majority of the company’s properties are in Colombia, where it pays the government a royalty or tax for its activities. Parex relies on a team of geologists, geophysicists, and technology like 3D seismic surveys to aid exploration activities. Oil output is marketed to a restricted group of South and North American players.

What makes Manulife Financial an attractive dividend bargain?

What makes Manulife Financial an attractive dividend bargain?

Manulife Financial Corp. (XTSX: MFC) incorporated in 1887 with headquarters in Toronto, is the largest insurance company in Canada and is aimed at providing financial products and services in Asia, Canada, US and internationally. It is the 28th largest fund manager in the world and has more than 125 years of experience with serving over 26 million customers.

The company runs through Wealth & Asset management businesses and Insurance and Annuity products. Additionally, the company holds and supplies investment management, counselling advisory and dealer services.
The company is the leading international financial services group that helps people make their decisions easier and lives better. It has over $1.3 trillion in assets under management and administration.

Invest in your future by investing in Artificial Intelligence sector

Invest in your future by investing in Artificial Intelligence sector

Artificial Intelligence is continuously innovating our industries and changing the way we live. It is no secret that anything that attracts attention and becomes an innovation quickly penetrates the stock market.

The United States has around 2000 AI companies in total. Last year, the global artificial intelligence market was valued at $93.5 billion and is expected to grow at 38% annually through 2030.

Are Green Bonds good investment option for long term retail Investors?

Are Green Bonds good investment option for long term retail Investors?

Green Bonds is a type of fixed income security issued to raise money for climate & environmental projects. Like any other type of bond, green bonds offer a stated return and represent a loan from an investor to a company, organization, or government agency.

Green bonds may come with tax incentives such as tax exemption and tax credits, making them a more attractive investment vs. a comparable taxable bond. Investors interested in green bonds should learn the diverse types and the pros and cons of investing before buying.

What Is Equity Research  and Why Is It Important?

What Is Equity Research and Why Is It Important?

There are many uncertainties surrounding the stock market, so investing in stocks has always been seen as a gamble. It is a common misconception in the stock market that success depends entirely on chance. A miracle may bring instant riches; a catastrophe may ruin all your hard work.

Everything is true to an extent, but equity research comes into play to protect people from the uncertainties of the stock market. Equity research acts as a timely and effective shield, ensuring the protection of investors.

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

Douglas Elliman Inc. (XYNS: DOUG) is a real estate company. Among other real estate-related services, it provides sales, rentals, and new development in combination with mortgages and title insurance. The company operates in two divisions: Real Estate Brokerage and Corporate and Other. The company makes revenue from Commission and other brokerage income from existing house sales, Commission and other brokerage income from development marketing, Property management income, and Title fees. 

How to survive bear market ?

How to survive bear market ?

As reflected in the Standard & Poor’s 500 and the Nasdaq Composite Index, a Bear Market is commonly defined as a stock market decline of 20% or more from its recent highs. Factors such as weak or declining economy, pandemics, wars, interest rate hikes, oil price movements, bursting market bubbles and unexpected high inflation figures can all contribute to a bear market.  

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.